UNSPSC 51313111: Cetirizine dihydrochloride

This classification denotes a histamine-1 receptor antagonist with the molecular formula C21H25ClN2O3.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 64O047KTOA, chemically known as acetic acid, (2-(4-((4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride, (+-)- but more generally known as cetirizine dihydrochloride, which bears US NIH Compound Identifier 55182.

European Medicines Agency schedules Cetirizine dihydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11803MIG. Most nations, for tariff and trade purposes, schedule cetirizine dihydrochloride under HS 29335995. SMILES: C1CCC(CC1)C(C2CCC(CC2)CL)N3CCN(CC3)CCOCC(=O)O.CL.CL.

UNSPSC 51313111 Cetirizine dihydrochloride is a Commodity code that nominally addresses a specific antihistamine active pharmaceutical ingredient, but recent state and local procurement activity shows a substantial mismatch between the code's labeled scope and what is actually being solicited under it. The single recent opportunity posted under this code—Seminole County, Florida's IFB60459723LAS—solicits naloxone and drug deactivation systems, not cetirizine dihydrochloride or any antihistamine product. The procurement calls for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building. This fundamental divergence between the code's pharmaceutical scope and the emergency-response and harm-reduction products actually being bought suggests either a data-entry error in the opportunity record or a systematic miscoding practice within Seminole County's procurement system.

Seminole County, Florida represents the only identified issuer under this code in the recent-opportunities dataset, posting the naloxone and deactivation-systems IFB on June 30, 2026, with a response deadline of July 26, 2023. (Note: the due date appears internally inconsistent with the posting date and should be verified against the original notice.) The contract carries a two-year initial term with a one-year renewal option and is potentially funded through FEMA, introducing federal compliance requirements including the Clean Air Act and Federal Water Pollution Control Act. Vendors must comply with E-Verify, maintain required insurance, and meet drug-free workplace certification. Given the code's apparent misalignment with actual procurement activity, business development professionals should treat this code as showing little relevant recent activity for cetirizine dihydrochloride or other antihistamine products and verify the correct UNSPSC classification for naloxone and drug-deactivation equipment before pursuing similar opportunities.